Download
s13063-021-05588-9.pdf 922,62KB
WeightNameValue
1000 Titel
  • Safety and preliminary efficacy of sequential multiple ascending doses of solnatide to treat pulmonary permeability edema in patients with moderate-to-severe ARDS—a randomized, placebo-controlled, double-blind trial
1000 Autor/in
  1. Schmid, Benedikt |
  2. Kredel, Markus |
  3. Ullrich, Roman |
  4. Krenn, Katharina |
  5. Lucas, Rudolf |
  6. Markstaller, Klaus |
  7. Fischer, Bernhard |
  8. Kranke, Peter |
  9. Meybohm, Patrick |
  10. Zwißler, Bernhard |
  11. Frank, Sandra |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-09-20
1000 Erschienen in
1000 Quellenangabe
  • 22(1):643
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s13063-021-05588-9 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450703/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Acute respiratory distress syndrome (ARDS) is a complex clinical diagnosis with various possible etiologies. One common feature, however, is pulmonary permeability edema, which leads to an increased alveolar diffusion pathway and, subsequently, impaired oxygenation and decarboxylation. A novel inhaled peptide agent (AP301, solnatide) was shown to markedly reduce pulmonary edema in animal models of ARDS and to be safe to administer to healthy humans in a Phase I clinical trial. Here, we present the protocol for a Phase IIB clinical trial investigating the safety and possible future efficacy endpoints in ARDS patients.!##!Methods!#!This is a randomized, placebo-controlled, double-blind intervention study. Patients with moderate to severe ARDS in need of mechanical ventilation will be randomized to parallel groups receiving escalating doses of solnatide or placebo, respectively. Before advancing to a higher dose, a data safety monitoring board will investigate the data from previous patients for any indication of patient safety violations. The intervention (application of the investigational drug) takes places twice daily over the course of 7 days, ensued by a follow-up period of another 21 days.!##!Discussion!#!The patients to be included in this trial will be severely sick and in need of mechanical ventilation. The amount of data to be collected upon screening and during the course of the intervention phase is substantial and the potential timeframe for inclusion of any given patient is short. However, when prepared properly, adherence to this protocol will make for the acquisition of reliable data. Particular diligence needs to be exercised with respect to informed consent, because eligible patients will most likely be comatose and/or deeply sedated at the time of inclusion.!##!Trial registration!#!This trial was prospectively registered with the EU Clinical trials register (clinicaltrialsregister.eu). EudraCT Number: 2017-003855-47 .
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal Critical care
lokal Double-Blind Method [MeSH]
lokal Permeability [MeSH]
lokal Study Protocol
lokal Respiratory Distress Syndrome/drug therapy [MeSH]
lokal Humans [MeSH]
lokal Treatment Outcome [MeSH]
lokal Peptides, Cyclic [MeSH]
lokal Respiratory Distress Syndrome/diagnosis [MeSH]
lokal Acute respiratory distress syndrome
lokal Pulmonary Edema/drug therapy [MeSH]
lokal Edema [MeSH]
lokal COVID-19 [MeSH]
lokal Extravascular lung water
lokal Pulmonary edema
lokal SARS-CoV-2 [MeSH]
lokal Solnatide
lokal Pulmonary Edema/diagnosis [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/U2NobWlkLCBCZW5lZGlrdA==|https://frl.publisso.de/adhoc/uri/S3JlZGVsLCBNYXJrdXM=|https://frl.publisso.de/adhoc/uri/VWxscmljaCwgUm9tYW4=|https://frl.publisso.de/adhoc/uri/S3Jlbm4sIEthdGhhcmluYQ==|https://frl.publisso.de/adhoc/uri/THVjYXMsIFJ1ZG9sZg==|https://frl.publisso.de/adhoc/uri/TWFya3N0YWxsZXIsIEtsYXVz|https://frl.publisso.de/adhoc/uri/RmlzY2hlciwgQmVybmhhcmQ=|https://orcid.org/0000-0001-5324-981X|https://frl.publisso.de/adhoc/uri/TWV5Ym9obSwgUGF0cmljaw==|https://frl.publisso.de/adhoc/uri/Wndpw59sZXIsIEJlcm5oYXJk|https://frl.publisso.de/adhoc/uri/RnJhbmssIFNhbmRyYQ==
1000 Hinweis
  • DeepGreen-ID: f1b6eff6c6a743d8b9ef175a3a70c191 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6465566.rdf
1000 Erstellt am 2023-11-16T14:57:10.464+0100
1000 Erstellt von 322
1000 beschreibt frl:6465566
1000 Zuletzt bearbeitet Fri Dec 01 02:29:16 CET 2023
1000 Objekt bearb. Fri Dec 01 02:29:16 CET 2023
1000 Vgl. frl:6465566
1000 Oai Id
  1. oai:frl.publisso.de:frl:6465566 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source